Free Trial
NASDAQ:COYA

Coya Therapeutics (COYA) Stock Price, News & Analysis

Coya Therapeutics logo
$6.10 +0.23 (+3.92%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$5.97 -0.13 (-2.15%)
As of 10/3/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Coya Therapeutics Stock (NASDAQ:COYA)

Advanced

Key Stats

Today's Range
$5.88
$6.19
50-Day Range
$5.25
$6.86
52-Week Range
$4.65
$10.24
Volume
67,386 shs
Average Volume
93,015 shs
Market Capitalization
$102.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.20
Consensus Rating
Moderate Buy

Company Overview

Coya Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

COYA MarketRank™: 

Coya Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 510th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Coya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Coya Therapeutics has a consensus price target of $16.20, representing about 165.6% upside from its current price of $6.10.

  • Amount of Analyst Coverage

    Coya Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Coya Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Coya Therapeutics is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Coya Therapeutics is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Coya Therapeutics has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Coya Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.67% of the float of Coya Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Coya Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Coya Therapeutics has recently increased by 19.15%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Coya Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Coya Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.67% of the float of Coya Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Coya Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Coya Therapeutics has recently increased by 19.15%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Coya Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Coya Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    1 people have searched for COYA on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 2 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Coya Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.00% of the stock of Coya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 39.75% of the stock of Coya Therapeutics is held by institutions.

  • Read more about Coya Therapeutics' insider trading history.
Receive COYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

COYA Stock News Headlines

Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.tc pixel
Coya completes FTD combination therapy trial enrolment
See More Headlines

COYA Stock Analysis - Frequently Asked Questions

Coya Therapeutics' stock was trading at $5.73 on January 1st, 2025. Since then, COYA shares have increased by 6.5% and is now trading at $6.10.

Coya Therapeutics, Inc. (NASDAQ:COYA) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.14. The business earned $0.16 million during the quarter, compared to the consensus estimate of $0.78 million.

Coya Therapeutics (COYA) raised $15 million in an initial public offering on Thursday, December 29th 2022. The company issued 3,050,000 shares at $5.00 per share.

Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Coya Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
8/12/2025
Today
10/04/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:COYA
CIK
1835022
Fax
N/A
Employees
6
Year Founded
2016

Price Target and Rating

High Price Target
$18.00
Low Price Target
$14.00
Potential Upside/Downside
+165.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.88 million
Net Margins
N/A
Pretax Margin
-4,966.75%
Return on Equity
-61.05%
Return on Assets
-53.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.43
Quick Ratio
7.43

Sales & Book Value

Annual Sales
$3.55 million
Price / Sales
28.75
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.37 per share
Price / Book
2.57

Miscellaneous

Outstanding Shares
16,730,000
Free Float
14,718,000
Market Cap
$102.05 million
Optionable
Not Optionable
Beta
0.19

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:COYA) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners